TURNER DANIEL K III 4
4 · Orexigen Therapeutics, Inc. · Filed Feb 6, 2012
Insider Transaction Report
Form 4
TURNER DANIEL K III
Director
Transactions
- Purchase
Common Stock
2011-12-22$1.45/sh+28,602$41,473→ 177,958 total(indirect: See Footnote) - Purchase
Common Stock
2011-12-22$1.45/sh+28,602$41,473→ 377,958 total(indirect: See Footnote) - Purchase
Warrant to Purchase Common Stock
2011-12-22$14.49/sh+28,602$414,443→ 28,602 total(indirect: See Footnote)Exercise: $0.00From: 2011-12-22Exp: 2021-12-22→ Common Stock (286,020 underlying) - Purchase
Warrant to Purchase Common Stock
2011-12-22$14.49/sh+28,602$414,443→ 28,602 total(indirect: See Footnote)Exercise: $0.00From: 2011-12-22Exp: 2021-12-22→ Common Stock (286,020 underlying)
Footnotes (3)
- [F1]The Common Stock and Warrants were sold as units at a purchase price of $15.94 per unit, each unit consisting of one share of Common Stock and one Warrant to purchase ten shares of Common Stock.
- [F2]The reported securities are owned directly by Montreux Equity Partners II SBIC, L.P. ("MEP II"). The voting and disposition of the shares held by MEP II are determined by Montreux Equity Management II SBIC, LLC ("MEM II"). Mr. Turner is a managing member of MEM II. Mr. Turner disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
- [F3]The reported securities are owned directly by Montreux Equity Partners III SBIC, L.P. ("MEP III"). The voting and disposition of the shares held by MEP III are determined by Montreux Equity Management III SBIC, LLC ("MEM III"). Mr. Turner is a managing member of MEM III. Mr. Turner disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.